Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for vTv Therapeutics (VTVT) over the last 9 years, with Q3 2025 value amounting to $18.7 million.

  • vTv Therapeutics' Non-Current Deffered Revenue changed 0.0% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $18.7 million for FY2024, which is 0.0% changed from last year.
  • vTv Therapeutics' Non-Current Deffered Revenue amounted to $18.7 million in Q3 2025, which was down 0.0% from $18.7 million recorded in Q2 2025.
  • vTv Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $18.7 million during Q2 2022, with a 5-year trough of $9000.0 in Q2 2021.
  • Its 5-year average for Non-Current Deffered Revenue is $15.4 million, with a median of $18.7 million in 2022.
  • Per our database at Business Quant, vTv Therapeutics' Non-Current Deffered Revenue plummeted by 9912.2% in 2021 and then surged by 20733333.33% in 2022.
  • vTv Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $9000.0 in 2021, then skyrocketed by 207333.33% to $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025.
  • Its Non-Current Deffered Revenue was $18.7 million in Q3 2025, compared to $18.7 million in Q2 2025 and $18.7 million in Q1 2025.